Solara Active Pharma – New 52 week high today. Technically, stock entering possibly in Phase 2 after a good Stage 1 basing period of 2.5 years.
Management has guided for 1400-1500cr topline and 230-260cr of EBITDA with Q4 EBITDA of 80-90cr. IF these numbers are delivered then current valuations are reasonable. IF their CRAMS business starts contributing – then this can become more than FY25 numbers play.
Disc: no position
| Subscribe To Our Free Newsletter |
